Kinnate Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- Kinnate Biopharma's estimated annual revenue is currently $12.9M per year.
- Kinnate Biopharma's estimated revenue per employee is $139,837
- Kinnate Biopharma's total funding is $194.5M.
- Kinnate Biopharma's current valuation is $678.6M. (January 2022)
- Kinnate Biopharma has 92 Employees.
- Kinnate Biopharma grew their employee count by 30% last year.
Kinnate Biopharma Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Kinnate Biopharma?
Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies. Headquartered in San Diego, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors. For more information, please visit www.kinnate.com.keywords:N/A
Number of Employees
Employee Growth %
Kinnate Biopharma News
(Nasdaq: KNTE) (Kinnate), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for...
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (Kinnate), a biopharmaceutical...
Kinnate Biopharma (NASDAQ:KNTE) said the first patient began treatment in a phase 1 trial of KIN-3248 in adults with advanced tumors...
Kinnate Biopharma Inc. has raised USD 35 million Series A financing for a joint venture in China. The financing was led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital. Kinnate Biopharma will be the majority shareholder in the joint venture. The ...
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China Veteran biopharmaceutical i ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|